412 related articles for article (PubMed ID: 17719296)
1. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.
Tang YD; Rinder HM; Katz SD
Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296
[TBL] [Abstract][Full Text] [Related]
2. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Dallob A; Luo WL; Luk JM; Ratcliffe L; Johnson-Levonas AO; Schwartz JI; Dishy V; Kraft WK; De Hoon JN; Van Hecken A; De Lepeleire I; Radziszewski W; Wagner JA; Lai E
Platelets; 2011; 22(7):495-503. PubMed ID: 21526889
[TBL] [Abstract][Full Text] [Related]
3. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
5. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacodynamics of clopidogrel.
Thebault JJ; Kieffer G; Cariou R
Semin Thromb Hemost; 1999; 25 Suppl 2():3-8. PubMed ID: 10440415
[TBL] [Abstract][Full Text] [Related]
7. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Gilard M; Arnaud B; Cornily JC; Le Gal G; Lacut K; Le Calvez G; Mansourati J; Mottier D; Abgrall JF; Boschat J
J Am Coll Cardiol; 2008 Jan; 51(3):256-60. PubMed ID: 18206732
[TBL] [Abstract][Full Text] [Related]
8. Response to aspirin and clopidogrel monitored with different platelet function methods.
Mani H; Linnemann B; Luxembourg B; Kirchmayr K; Lindhoff-Last E
Platelets; 2006 Aug; 17(5):303-10. PubMed ID: 16928602
[TBL] [Abstract][Full Text] [Related]
9. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
Thebault JJ; Kieffer G; Lowe GD; Nimmo WS; Cariou R
Semin Thromb Hemost; 1999; 25 Suppl 2():9-14. PubMed ID: 10440416
[TBL] [Abstract][Full Text] [Related]
10. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Mannini L; Marcucci R; Paniccia R; Antonucci E; Giglioli C; Valente S; Gori AM; Prisco D; Gensini GF; Abbate R
Clin Hemorheol Microcirc; 2006; 35(1-2):175-81. PubMed ID: 16899924
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty.
Cassar K; Ford I; Greaves M; Bachoo P; Brittenden J
Br J Surg; 2005 Feb; 92(2):159-65. PubMed ID: 15609386
[TBL] [Abstract][Full Text] [Related]
12. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?
Swallow RA; Agarwala RA; Dawkins KD; Curzen NP
Platelets; 2006 Sep; 17(6):385-92. PubMed ID: 16973499
[TBL] [Abstract][Full Text] [Related]
13. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
[TBL] [Abstract][Full Text] [Related]
14. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Storey RF; Bliden KP; Patil SB; Karunakaran A; Ecob R; Butler K; Teng R; Wei C; Tantry US; Gurbel PA;
J Am Coll Cardiol; 2010 Jul; 56(3):185-93. PubMed ID: 20620737
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
[TBL] [Abstract][Full Text] [Related]
16. Effect of increased aspirin dose after stenting in association with ClOpidogrel: the FIASCO randomized study.
Cuisset T; Frere C; Quilici J; Uhry S; Morange PE; Mouret JP; Gaborit B; Bali L; Moro PJ; Lambert M; Bonnet JL
Thromb Res; 2009 May; 124(1):33-6. PubMed ID: 18990434
[TBL] [Abstract][Full Text] [Related]
17. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Serebruany VL; Malinin AI; Atar D
Cardiology; 2007; 107(4):307-12. PubMed ID: 17264511
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets.
O'Kane PD; Reebye V; Ji Y; Stratton P; Jackson G; Ferro A
J Mol Cell Cardiol; 2008 Aug; 45(2):223-9. PubMed ID: 18606420
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
20. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study.
Velik-Salchner C; Maier S; Innerhofer P; Streif W; Klingler A; Kolbitsch C; Fries D
Anesth Analg; 2008 Dec; 107(6):1798-806. PubMed ID: 19020120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
